Additional family of CombiCult® patents granted in USA, Europe, Australia and Singapore

Plasticell, the biotechnology company developing regenerative drugs using high throughput stem cell technologies, has announced that a further family of patents, offering additional protection of its proprietary cell culture technology, Combinatorial Cell Culture™ (CombiCult®), have been granted by the US Patent Office, European Patent Office, Australian Patent Office and Intellectual Property Office of Singapore. The newly granted patents cover the use of nanomaterial tags [...]

November 11th, 2013|Press Releases|

Plasticell and Progenitor Labs seed cell therapy activities at the Stevenage Bioscience Catalyst open innovation campus

Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation bioscience campus, is pleased to welcome regenerative medicine companies Plasticell Ltd and Progenitor Labs as tenants. Progenitor Labs is a drug discovery spin-off from Plasticell and recently received £4m in funding from SR One, the corporate venture arm of GlaxoSmithKline (GSK). Cell therapy and regenerative medicine is a focus of SBC’s [...]

June 10th, 2013|Press Releases|

Licenced from Plasticell, EMD Millipore Launches OsteoMAX-XF™, a Fully-defined, Xeno-free Mesenchymal Stem Cell Osteogenic Differentiation Medium

EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, and Plasticell of London, UK, today announced the availability of OsteoMAX-XF™, the first fully defined, xeno-free human mesenchymal stem cell differentiation medium for the differentiation of mesenchymal stem cells into osteocytes.  Mineralization can be detected in less than one week, whereas competing products that contain serum require approximately [...]

May 9th, 2013|Press Releases|

Plasticell’s regenerative medicine drug discovery spin-off Progenitor Labs secures £4m financing from GSK’s corporate venture fund SR One

Investment from SR One, GlaxoSmithKline’s Corporate Venture Fund, will fund company’s programme to discover small molecule drugs that regenerate specific tissues of the body. Progenitor Labs Ltd (Progenitor) has announced that it has raised £4 million ($5.8million) in seed financing from SR One’s UK Fund. Progenitor is a pioneering regenerative medicine company that develops drugs to regenerate specific tissues of [...]

March 11th, 2013|Press Releases|

Plasticell and EMD Millipore complete licensing deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media

Plasticell, the UK stem cell differentiation specialist has licensed EMD Millipore, the Life Science Division of Merck KGaA, to distribute a superior, single-application osteogenic medium discovered using the award winning, massively parallel combinatorial screening system, CombiCult®. The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the terms of the contract, [...]

August 14th, 2012|Press Releases|

Plasticell and Veritas announce an exclusive distribution agreement in Japan

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has today announced that it has engaged Veritas Corporation of Tokyo as the exclusive distributor for all of its services and products, including CombiCult®, in Japan. CombiCult® breaks the major bottleneck in stem cell research and development programmes – the discovery of optimised stem cell differentiation [...]

June 14th, 2012|Press Releases|

Plasticell announces grant of fundamental CombiCult® patents in USA and Japan

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, today announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan.  Patents covering CombiCult™ have now been issued in Europe, USA, Japan, Australia and Singapore. CombiCult™ breaks the major bottleneck in stem cell research and development programmes [...]

February 13th, 2012|Press Releases|

Plasticell to collaborate with Pfizer, Cellzome and University of Sheffield in a £1.4 million Technology Strategy Board-funded stem cell project

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced that the Technology Strategy Board has funded a research consortium comprising of Plasticell, Pfizer (Neusentis) and the University of Sheffield, led by Cellzome. The project will develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behaviour. The Technology [...]

January 10th, 2012|Press Releases|

Plasticell wins Technology Strategy Board funding for £1.5 million stem cell manufacturing project

Plasticell has announced that the Technology Strategy Board has made a further investment in the Company’s flagship technology, CombiCult™, the high throughput technology designed to solve the major bottleneck in stem cell research and development. The Technology Strategy Board will provide a grant of approximately £750k towards a £1.5 million project entitled ‘High Throughput Platform for the Discovery of GMP-Compatible [...]

December 6th, 2011|Press Releases|

Plasticell Delivers Differentiation Protocols to Stemnion, Inc.

Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced the successful completion of a collaboration with Stemnion, Inc. (Pittsburgh, PA), a US biotechnology company focused on the applications of stem cells derived from human placentas. Plasticell used its flagship technology CombiCult™ to discover multiple novel, serum-free protocols that direct the differentiation of Stemnion’s [...]

August 3rd, 2011|Press Releases|

Plasticell‘s CombiCult™ v2.0 platform wins international R&D 100 Award

Plasticell’s high throughput screen for stem cell differentiation joins list of the most significant technology products developed globally in the last 49 years Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has won the prestigious R&D 100 Award for its CombiCult™v2.0 system. The CombiCult™ platform is a high-throughput combinatorial screening technology that allows scientists [...]

June 23rd, 2011|Press Releases|

Plasticell Spins Out Regenerative Drug Discovery Venture

New demerged business called ‘Progenitor Labs’ Plasticell Ltd, the biotechnology company developing high throughput stem cell technologies, has announced today that following its recent £3.5m financing, it has undergone a strategic re-structuring to enable the Company to focus on its award winning CombiCult™ technology for stem cell differentiation. Consequently, Plasticell Ltd has demerged its regenerative drug discovery unit into a [...]

April 13th, 2011|Press Releases|

Plasticell completes £3.5 million financing round

Capital injection to expand business development and marketing initiatives Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced it has completed a two-part equity financing, raising a total of £3.5 million from new and existing investors. The first tranche of the financing, in which £1.5 million was drawn down in April 2009, was [...]

January 31st, 2011|Press Releases|

Plasticell signs technology agreement with Sigma-Aldrich

Collaboration to produce novel turnkey solution for stem cell research Plasticell, the biotechnology company specialising in high throughput technologies for directed stem cell differentiation, has announced the signing of a collaboration agreement with Sigma-Aldrich, a leading provider of technologies and reagents to the life science research market. In the collaboration, Sigma-Aldrich will use its CompoZr® Zinc Finger Nuclease Technology to [...]

November 29th, 2010|Press Releases|

Plasticell signs screening collaboration with UCB. First in kind deal to partner small molecule drugs for stem cell research

Plasticell, the biotechnology company specialising in the use of innovative high throughput technologies in stem cell research, has announced signing of a collaboration agreement with the biopharmaceutical company, UCB. Under the terms of the agreement, UCB will supply Plasticell with drug compound libraries with known biological targets. Plasticell will screen these using its award-winning CombiCult technology to discover new cell [...]

November 8th, 2010|Press Releases|

Plasticell validates regenerative drug screen in collaboration with GSK

London, 12 March 2009 … Research announced today by Plasticell, a leading UK regenerative medicine biotech company, shows how embryonic stem cells can be used to discover novel small molecules capable of encouraging the body to regenerate, potentially paving the way for the development of drugs to repair organs damaged by disease or ageing. Plasticell used its proprietary technologies to [...]

March 12th, 2009|Press Releases|